Hosted on MSN
Pfizer settles to delay Vyndamax generics until 2031
Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
BridgeBio (BBIO) rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's (PFE ...
Today’s illicit chemists can quickly cook up drugs far more dangerous than fentanyl. By Jonathan Corum and Matt Richtel Illicit labs are creating new synthetic drugs at breakneck speed. Dangerous, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results